Triple-negative breast cancer (TNBC), a particularly aggressive and chemoresistant subtype, lacks three key receptors, i.e., estrogen receptor alpha (Erα), progesterone receptors (PRs), and HER2, making endocrine therapy ineffective [4]. Here, ESR1 is linked to triple-negative breast carcinoma.